Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010

Similar documents
PET/CT Frequently Asked Questions

Dr Sneha Shah Tata Memorial Hospital, Mumbai.

New Visions in PET: Surgical Decision Making and PET/CT

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors

POSITRON EMISSION TOMOGRAPHY (PET)

Positron Emission Tomography in Lung Cancer

Radiology Pathology Conference

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.

An Introduction to PET Imaging in Oncology

Lymphoma Read with the experts

objectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University

Clinical indications for positron emission tomography

Breast Cancer PET/CT Imaging Protocol

PET IMAGING (POSITRON EMISSION TOMOGRAPY) FACT SHEET

Clinical summary. Male 30 year-old with past history of non-seminomous germ cell tumour. Presents with retroperitoneal lymphadenopathy on CT.

PET/CT in lung cancer

F NaF PET/CT in the Evaluation of Skeletal Malignancy

Ryan Niederkohr, M.D. Slides are not to be reproduced without permission of author

Page: 1 of 29. For this policy, PET scanning is discussed for the following 4 applications in oncology:

Pitfalls in Oncologic Diagnosis with PET CT. Nononcologic Hypermetabolic Findings

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Tumor Board Discussions: Case 1

Lugano classification: Role of PET-CT in lymphoma follow-up

M etastatic disease influences patient management; Whole body PET/CT for initial staging of choroidal melanoma SCIENTIFIC REPORT

Oncologic Applications of PET Scanning

Imaging in gastric cancer

Lung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09

Appendix 1: Regional Lymph Node Stations for Staging Esophageal Cancer

Direct Comparison of 18 F-FDG PET and PET/CT in Patients with Colorectal Carcinoma

Diagnostic challenge: Sclerosing Hemangioma of the Lung. Department of Medicine, Division of Pulmonary and Critical Care, Lincoln Medical and

Nuclear medicine in oncology. 1. Diagnosis 2. Therapy

The Role of PET / CT in Lung Cancer Staging

Imaging of Pulmonary Tuberculosis with 18 F-Fluoro-Deoxy-Glucose and

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Testicular relapse of non-hodgkin Lymphoma noted on FDG-PET

Imaging Features of Sarcoidosis on MDCT, FDG PET, and PET/CT

PET/CT in breast cancer staging

Bone and CT Scans Are Complementary for Diagnoses of Bone Metastases in Breast Cancer When PET Scans Findings Are Equivocal: A Case Report

Radiological staging of lung cancer. Shukri Loutfi,MD,FRCR Consultant Thoracic Radiologist KAMC-Riyadh

Colorectal Cancer and FDG PET/CT

FDG-PET/CT for cancer management

Imaging in Metastatic Melanoma. Nilanthi Gunawardane Gillian Lieberman, MD March 2008

WHAT DOES PET IMAGING ADD TO CONVENTIONAL STAGING OF HEAD AND NECK CANCER PATIENTS?

Exercise 15: CSv2 Data Item Coding Instructions ANSWERS

Staging Colorectal Cancer

Nuclear Sciences and Medicine

CLINICAL PRESENTATION AND RADIOLOGY QUIZ QUESTION

ROLE OF PET-CT SCAN IN LOCALLY ADVANCED HEAD & NECK CANCER: A Prospective Study

PET/MR:Techniques, Indications and Applications

Radiological Manifestations of Metastatic Melanoma

FDG PET/CT in Lung Cancer Read with the experts. Homer A. Macapinlac, M.D.

FieldStrength. Leuven research is finetuning. whole body staging

Positron emission tomography/computer tomography in the evaluation of head and neck cancer treatment

Accurate tumor staging is essential for choosing the

Evaluation of Lung Cancer Response: Current Practice and Advances

42 yr old male with h/o Graves disease and prior I 131 treatment presents with hyperthyroidism and undetectable TSH. 2 hr uptake 20%, 24 hr uptake 50%

PET CT for Staging Lung Cancer

Prof. Dr. NAGUI M. ABDELWAHAB,M.D.; MARYSE Y. AWADALLAH, M.D. AYA M. BASSAM, Ms.C.

Esophageal Cancer Initially Thought to be Accompanied by a Solitary Metastasis to an Intrathoracic Paraaortic Lymph Node

Imaging of the cisterna chyli on PET-CT in patients with known malignancy: Report of two cases

Primary Pulmonary Colloid Adenocarcinoma: How Can We Obtain a Precise Diagnosis?

Zurich, January 19, 2018

Understanding the Diagnostic and Prognostic Role of Imaging in the Evaluation of an Anterior Mediastinal Mass

VIII. 9. FDG-PET for Diagnosis of an Advanced Jejunal Adenocarcinoma with Distant Metastases, Compared with Gallium Scintigraphy

Positron Emission Tomography (PET) for Staging Low-Grade Non-Hodgkin s Lymphomas (NHL)

L hyperfixation dans le suivi des lymphomes représente-t-elle toujours une maladie active?

ROLE OF PET-CT IN BREAST CANCER, GUIDELINES AND BEYOND. Prof Jamshed B. Bomanji Institute of Nuclear Medicine UCL Hospitals London

Indications of PET/CT in oncology

Hybrid Imaging SPECT/CT PET/CT PET/MRI. SNMMI Southwest Chapter Aaron C. Jessop, MD

Management of Neck Metastasis from Unknown Primary

Case Report PET/CT Imaging in Oncology: Exceptions That Prove the Rule

1 Introduction. 2 Materials and methods. LI Na 1 LI Yaming 1,* YANG Chunming 2 LI Xuena 1 YIN Yafu 1 ZHOU Jiumao 1

Nuclear Medicine in Oncology

PET in Rectal Carcinoma

Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: A clinical case with literature review

Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules

Lung. 10/24/13 Chest X-ray: 2.9 cm mass like density in the inferior lingular segment worrisome for neoplasm. Malignancy cannot be excluded.

ANZUP SURVEILLANCE RECOMMENDATIONS FOR METASTATIC TESTICULAR CANCER POST-CHEMOTHERAPY

PET imaging of cancer metabolism is commonly performed with F18

Radionuclide detection of sentinel lymph node

Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC

Subject: PET Scan With or Without CT Attenuation. Original Effective Date: 11/7/2017. Policy Number: MCR: 610. Revision Date(s): Review Date:

The Diagnostic Value of PET/CT in Breast Cancer Recurrence and Metastases

THE ROLE OF CONTEMPORARY IMAGING AND HYBRID METHODS IN THE DIAGNOSIS OF CUTANEOUS MALIGNANT MELANOMA(CMM) AND MERKEL CELL CARCINOMA (MCC)

Index. pet.theclinics.com. Note: Page numbers of article titles are in boldface type.

CT PET SCANNING for GIT Malignancies A clinician s perspective

The Use of PET Scanning in Urologic Oncology

Evaluation and Management of Thyroid Nodules. Nick Vernetti, MD, FACE Palm Medical Group Las Vegas, Nevada

Risk Factors for Occult Mediastinal Metastases in Clinical Stage I Non-Small Cell Lung Cancer

Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer

Subject Index. Dry desquamation, see Skin reactions, radiotherapy

PET with the glucose analog, 18 F-FDG PET, is increasingly

Molecular Imaging and Cancer

Adam J. Hansen, MD UHC Thoracic Surgery

Learning Objectives. 1. Identify which patients meet criteria for annual lung cancer screening

LYMPHATIC DRAINAGE IN THE HEAD & NECK

Research Article The Advantage of PET and CT Integration in Examination of Lung Tumors

ARTICLE. Imaging of metastatic melanoma

Transcription:

Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010 Self Assessment Module on Nuclear Medicine and PET/CT Case Review FDG PET/CT IN LYMPHOMA AND MELANOMA Submitted by: Lalitha Ramanna, MD Director of Nuclear Medicine Little Company of Mary Hospital Clinical Associate Professor of Radiology Department of Nuclear Medicine Keck School of Medicine of USC Cases 27-39 Case 27: Pre and post therapy PET scans in a 37 year old woman with lymphoma. a. Good response b. Poor response c. Indeterminate d. Biopsy indicated Answer: a is correct The literature data supports the fact that PET scan is very effective in assessing therapy response. b. Incorrect because there is no evidence for FDG uptake in the follow up scan. c. Incorrect because of complete resolution of metabolic activity on the post therapy scan d. Incorrect as PET scan has been shown to be good indicator of good response Kostakoglu et al; 18F-FDG PET Evaluation of the response to therapy forlymphoma and for breast, Lung, and colorectal carcinoma. Journal of Nuclear Medicine 2003; 44(2):224-239 ase 28: PET scan with an anterior mediastinal density and lower neck metabolic activity. a. High grade lymphoma a. Benign process b. Inflammatory lymphadenopathy c. Sub-sternal thyroid Answer: b is correct This is the most likely process as there is no metabolic activity in the anterior mediastinal density. The lower neck and upper chest activity is related to brown fat. a. is incorrect as high grade lymphomas have high FDG uptake. c. is incorrect as the pattern of uptake is typical for brown fat activity. d. is incorrect as the anterior mediastinal density is more focal and not related to thyroid gland. Page 1 of 6

References: 1) Hubner et al; Differentiating Benign from Malignant Lung Lesions using Quantitative Parameters of FDG PET Images, Clinical Nuclear Medicine 1996; 21(12):941-949. 2) Cohade et al; Uptake in Supraclavicular Area Fat ( USA-Fat ): Description on 18F-FDG PET/CT; J Nucl Med 2003; 44:170 176 Case 29: 45 Yr old man with PET scan for suspected lymphoma. a. Negative for lymphoma. b. Physiologic uptake c. Positive for lymphoma d. Low grade lymphoma Answer: C is correct: c. is correct because of intense right nasal uptake proven to be lymphoma. a. is incorrect because there is intense of intense and asymmetric metabolic activity in the right nasal cavity. b. is incorrect because of intense and asymmetric right nasal cavity uptake,unlikely physiological d. is incorrect because of high metabolic activity. Okada et al; The use of FDG-PET in the detection and management of malignant lymphoma; Correlation of uptake with prognosis. J. Nucl. Med. 2004; 32:686-691 Case 30: Patient with weight loss and fever has advanced lymphoma. Therapeutic response is best assessed by a. CT scan b. PET scan, visual c. PET scan, SUV d. PET and CT scan Answer b is correct: B is correct as it has been shown that visual analysis is sufficient in the clinical scenario. a. is incorrect as CT scan is relatively insensitive to measure therapeutic response. c. is incorrect as SUV does not add to visual analysis. d. is incorrect because often residual lesions are seen on CT scan without metabolic activity. Juweid ME et al; Use of Positron tomography for response assessment of lymphoma: Consensus of the imaging Subcommittee of International Harmonization Project in Lymphoma. J. Clin Oncol 2007; 25(5):571-8 Case 31: 10 Yr. old boy S/P chemotherapy for lymphoma. Therapy response assessment in this case is a. Easy and straightforward. b. Good response; No metabolic activity c. Poor response; Persistent activity d. Not easy and complicated Page 2 of 6

D is correct because in pediatric and young adults there is thymic rebound with FDG uptake post therapy and may not be able to separate from residual disease. a. is incorrect because of thymic rebound. b. is incorrect because normal thymic uptake may be present even if good response in pediatric group. c. is incorrect because persistent FDG uptake in thymus may be present with good response because of cellular proliferation and FDG uptake. 1) Ferdinand, B, Gupta, P. and Kramer, EL; Spectum of Thymic activity at 18F-FDG PET. RadioGraphics 2004; 24:1611 1616 2) Miller et al; Role of 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients. J Comput Assist Tomogr 2006; 30:689-94. Case 32: Patient with RUQ pain had liver biopsy. The pathology was a. hemangioma b. hepatoma c. lymphoma d. Stage 1 lymphoma D is correct based on AJCC staging. a. is incorrect as the blood pool images were negative. b. is possible as hepatomas may have low uptake c. is incorrect, only liver is involved. References: 1) AJCC Cancer Staging Manual, fifth Edition. American joint Committee on Cancer. 2) Delbeke, D. et al; Evaluation of Benign vs Malignant Hepatic Lesions with Positron Emission Tomography. Arch Surg. 1998; 133:510-516. Case 33: Patient with lymphoma s/p chemotherapy a. Residual lymphoma b. Physiologic FDG uptake c. Cannot evaluate without baseline study d. Artifact D is correct because of significant residual barium and artifactual increase in FDG uptake In lower abdomen. a. is incorrect because the non-attenuation corrected images show no FDG uptake b. is incorrect because non AC images show no uptake. c. is incorrect because the teaching point in this case is to look at both AC and Non AC images to separate artifacts from true findings. Sureshbabu et al; PET imaging artifacts. Journal of Nuclear Medicine Technology 2005; 33(3):2005 156-161. Page 3 of 6

Case 34: 4.5 cm melanoma and PET scan; The TNM classification is a. T3, N3, M0 b. T4, N2, M0 c. T4, N1, M0 d. T3, N2, M1 Answer b is correct: B is correct since greater than 4 cm melanoma is T4 and greater than 1 node is N2 and no evidence for metastasis = M0 a. is incorrect based on TNM classification c. is incorrect because more than one lymph node involved d. is incorrect because there is no evidence for metastasis AJCC, Cancer Staging Manual, 5th Edition, American Cancer Society Case 35: 89 yr old man for restaging of high risk melanoma. The most accurate statement regarding PET scan in melanoma staging; a. Highly sensitive and specific b. Highly specific but not sensitive c. Highly sensitive and not specific d. Highly sensitive and specific with the exception of brain A, b, and c are incorrect because PET scan is both sensitive and specific when compared to conventional imaging for melanoma staging. However, small brain lesions are best imaged with MRI. References: 1) Rinne D, Baum RP, Hor G, Kaufmann R.; Primary Staging and Follow up of High Risk Melanoma Patients with Whole-Body 18-F-Fluorodeoxyglucose Positron Emission Tomography, Results of a Prospective Study of 100 Patients. Cancer 1998; Volume 82(9):1664-71. 2) Rohren et al; Screening for Cerebral Metastases with FDG PET in Patients Undergoing Whole Body Staging of Non-cerebral Nervous System Malignancy. Radiology 2003; 226(1):181-187. Case 36: PET scan for restaging of Melanoma; The scan is positive for metastases in a. Bone b. Lung c. Bone and lung. d. No definite metastases Answer d is correct a. is incorrect as increased uptake in the spine is related to vertebroplasty artifact. b. the lung nodules are too small for resolution. c. is incorrect as explained above. Page 4 of 6

Gupta et al; Probability of malignancy in solitary pulmonary nodules using fluorine -18-FDG and PET. J Nucl Med 1996; 37:943-947. Case 37: The correct statement in this patient with melanoma is a. PET scan has replaced lymphoscintigraph b. PET scan is not very sensitive for palpable lymph node metastasis c. Sentinel lymph node dissection is the standard of care d. The sensitivity and specificity of PET for melanoma is 50% Answer c is correct a. is incorrect, because PET scan does not detect microscopic metastases. b. is incorrect because PET scan is more sensitive than conventional imaging for lymph node evaluation. d. is incorrect because the reported sensitivity is greater than 90% for melanoma staging. Macapinlac et al; FDG PET and PET/CT imaging in lymphoma and melanoma. Cancer J 2004; 10:262-270 Case 38: S/P melanoma resection one week prior to PET scan a. Residual melanoma is excluded. b. Negative for lymph node metastases. c. CT scan would be helpful for pulmonary metastases. d. B and C PET scan is more sensitive for detection of lymph node metastases and CT is more sensitive for detection of small pulmonary metastases. a. is incorrect because post surgical changes may obscure residual disease. Gritters et al; Initial assessment of positron emission tomography using 2- fluoro-2-deoxy- D- glucose in the imaging of malignant melanoma. J Nucl Med.1993: 34:1420-1427 Case 39: In the initial diagnostic ABCD criteria for melanoma, the D stands for a. depth b. diameter c. drainage, lymph node d. duration of lesion Answer b is correct a. is incorrect as depth cannot be assessed visually. c. is incorrect as the lymph nodes are evaluated histologically. d. is incorrect, asymmetry, border, color and diameter greater than 6 mm are of concern for cutaneous melanoma Page 5 of 6

1) Dial WF; ABCD rule aids in preoperative diagnosis of malignant melanoma. Cosmetic Dermatol 1995; 8(3):32-4, 1995. 2) Friedman RJ, Rigel DS, and Kopf AW; Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA Cancer J Clin 1985; 35(3):130-51 3) Friedman RJ, Rigel DS, Silverman M, and Kopf AW; The continued importance of early detection of malignant melanoma. CA 1991; 41:201-26, 1991 Page 6 of 6